Bio Plus Co

Bio Plus Co OCF Margin

The Operating Cash Flow Margin of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 16.21 %. In the previous year, Operating Cash Flow Margin was 33.56 % — a change of -51.69% (lower).

OCF Margin

16.21 %

YoY

-51.69%

Last updated:

Operating Cash Flow Margin of Bio Plus Co is 2025 16.21 % . Operating Cash Flow Margin of Bio Plus Co was 2024 33.56 % . It decreases by -51.69% lower compared to the previous year.

The Bio Plus Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
28.53 KRW
Jan 1, 2019
29.16 KRW
Jan 1, 2020
41.22 KRW
Jan 1, 2021
35.68 KRW
Jan 1, 2022
23.55 KRW
Jan 1, 2023
24.66 KRW
Jan 1, 2024
33.56 KRW
Jan 1, 2025
16.21 KRW
The Bio Plus Co OCF Margin history
YEAROCF MarginYoY
16.21 %-51.69%
33.56 %+36.10%
24.66 %+4.70%
23.55 %-33.99%
35.68 %-13.42%
41.22 %+41.34%
29.16 %+2.23%
28.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Operating Cash Flow Margin of Bio Plus Co is 16.21 % in 2025.

Operating Cash Flow Margin of Bio Plus Co changed from 33.56 % to 16.21 %, representing a -51.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bio Plus Co

All Key Metrics — Bio Plus Co